Lung Cancer Clinical Trial
A Study to Assess Disease Activity of Intravenously (IV) Infused Telisotuzumab Vedotin in Adult Participants With Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. The purpose of this study is to determine how telisotuzumab vedotin affects the disease state in adult participants with previously untreated participants with MET amplified non-squamous NSCLC. Change in disease activity will be assessed.
Telisotuzumab vedotin is an investigational drug being developed for the treatment of MET amplified non-squamous NSCLC. Participants receive intravenously (IV) infused of telisotuzumab vedotin. Approximately 70 adult participants with previously untreated MET amplified locally advanced/metastatic non-squamous NSCLC will be enrolled in the study in approximately 110 sites worldwide.
Participants will receive IV telisotuzumab vedotin every 2 weeks until meeting study drug discontinuation criteria.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Must have MET amplification in tumor tissue as determined by the Sponsor-designated central laboratory or in plasma and/or tissue by a Sponsor-approved assay.
Must have histologically documented non-squamous cell non-small cell lung cancer (NSCLC) that is locally advanced or metastatic.
Must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
Must have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
Participant may have received prior adjuvant/neoadjuvant systemic chemotherapy and/or radiation if it was completed >= 6 months before participant's first dose of study drug.
Metastases to the central nervous system (CNS) are eligible only after definitive therapy is provided as noted in the protocol.
History of radiation pneumonitis in the radiation field (fibrosis) is permitted.
Have adenosquamous histology.
Alterations in EGFR, ALK, ROS1, or BRAF that predict sensitivity to targeted therapy. Participants with other alterations that are candidates for available targeted therapy.
Prior systemic therapy for locally advanced/metastatic NSCLC.
Have a history of other malignancies except those noted in the protocol.
Have a history of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan.
Received prior c-Met-targeted antibodies.
Have NSCLC that is eligible for treatment with curative intent.
Have unresolved clinically significant adverse events (AEs) >= Grade 2 from prior anticancer therapy, except for alopecia or anemia.
Have had major surgery within 21 days prior to the first dose of telisotuzumab vedotin.
Have clinically significant condition(s) as noted in the protocol.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 63 Locations for this study
Renton Washington, 98055, United States
Clayton Victoria, 3168, Australia
Beijing Beijing, 10014, China
Guangzhou Guangdong, 51016, China
Harbin Heilongjiang, 15008, China
Wuhan Hubei, 43002, China
Wuhan Hubei, 43006, China
Jinan Shandong, 25160, China
Chengdu Sichuan, 61004, China
Hangzhou Zhejiang, 31000, China
Hangzhou Zhejiang, 31002, China
Hangzhou Zhejiang, 31002, China
Chengdu , 61004, China
Shanghai , 20003, China
Wuhan , 43003, China
Lille Hauts-de-France, 59037, France
Bron , 69500, France
Clermont Ferrand , 63011, France
Gießen Hessen, 35392, Germany
Gauting , 82131, Germany
Oldenburg , 26121, Germany
Ramat Gan Tel-Aviv, 52656, Israel
Jerusalem Yerushalayim, 91120, Israel
Haifa , 31096, Israel
Kfar Saba , 44281, Israel
Petakh Tikva , 49414, Israel
Milan Milano, 20132, Italy
Monza Monza E Brianza, 20900, Italy
Candiolo Torino, 10060, Italy
Ancona , 60126, Italy
Rome , 00144, Italy
Kashiwa-shi Chiba, 277-8, Japan
Fukuoka-shi Fukuoka, 811-1, Japan
Sapporo-shi Hokkaido, 060-8, Japan
Osaka-shi Osaka, 541-8, Japan
Sunto-gun Shizuoka, 411-8, Japan
Chuo-ku Tokyo, 104-0, Japan
Yangsan-si Gyeongsangnamdo, 50612, Korea, Republic of
Seoul Seoul Teugbyeolsi, 03722, Korea, Republic of
Cheongju , 28644, Korea, Republic of
Daegu , 41931, Korea, Republic of
Seoul , 06351, Korea, Republic of
Ploiesti Prahova, 10033, Romania
Bucharest , 03017, Romania
Cluj Napoca , 40001, Romania
Cluj , 40728, Romania
Las Palmas de Gran Canaria Las Palmas, 35016, Spain
Alcorcon Madrid, 28922, Spain
Barcelona , 08028, Spain
Barcelona , 08907, Spain
Zaragoza , 50009, Spain
Kaohsiung , 807, Taiwan
Kaohsiung , 833, Taiwan
Tainan , 704, Taiwan
Taoyuan City , 333, Taiwan
Adana , 01060, Turkey
Ankara , 06200, Turkey
Ankara , 06560, Turkey
Antalya , 07059, Turkey
Edirne, Istanbul , 22030, Turkey
Istanbul , 34722, Turkey
Izmir , 35110, Turkey
Leicester England, LE1 5, United Kingdom
Birmingham , B15 2, United Kingdom
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.